Antifibrinolytic Drugs Market by Indication (Gynecology, Hereditary Angiedema, Fibrinolytic Response Testing, Surgeries, and Others) and End user (Hospitals & Clinics, Ambulatory Surgical Centers, and Healthcare Specialty Process): Global Opportunity Analysis and Industry Forecast, 20192026
- Published Date: 2020-10-18
- Report ID: 3859
- Pages: 165
-
Format:
The global antifibrinolytic drugs market was valued at $1,3593 million in 2018 and is expected to reach $1,9333 million by 2026, registering a CAGR of 4.5% from 2019 to 2026. Antifibrinolytic is a type of drug that helps in the formation of blood clot. These drugs prevent the breakdown of fibrin, which is the main protein involved in blood clotting. These drugs can be used to prevent serious bleeding in patients suffering from life threatening conditions such as hemophilia, very heavy menstrual bleeding, or some types of vascular tumors. They are also widely used to prevent or control bleeding during or after surgery or after a traumatic injury. An increase in usage of these drugs has been witnessed since past few years, owing to their increased applications.
Rise in medical surgeries including dental and cardiac, accidental trauma, and increase in incidence of angioedema across the globe are the major factors that drive the antifibrinolytic drugs market growth. Antifibrinolytic drugs play a crucial role in the prevention of clot lysis and blood loss. Considerable surge in prevalence of bleeding disorders propels the antifibrinolytic drugs market growth. However, high cost of these drugs hamper the market growth. Furthermore, increase in research & development for developing novel innovative antifibrinolytic drugs is anticipated to create new opportunities for the market.
The market is segmented on the basis of indication, end-users, and region. On the basis of indication, it is classified into gynecology, hereditary angiedema, fibrinolytic response testing, surgeries, and others. By end user, it is divided into hospitals & clinics, ambulatory surgical centers, and healthcare specialty process. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
By Indication
Gynecology
Hereditary Angiedema
Fibrinolytic Response Testing
Surgeries
Others
By End User
Hospitals & Clinics
Ambulatory Surgical Centers
Trauma Centers
By Region
North America
o U.S.
o Canada
o Mexico
Europe
o Germany
o France
o UK
o Italy
o Rest of Europe
Asia Pacific
o Japan
o China
o India
o Rest of Asia-Pacific
LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA
KEY PLAYERS
Acic Fine Chems
Xanodyne Pharmaceuticals
Aurobindo Pharma Ltd
Akorn
Mylan N.V.
Pfizer (GenMed)
Sanofi SA
Zydus Cadila
Takeda
Amerigen Pharms Ltd
Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models
Chapter 2: Executive Summary
2.1. Key Findings of The Study
2.2. Cxo Perspective
Chapter 3: Market Overview
3.1. Market Definition And Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.3. PorterS Five Forces Analysis
3.3.1. Moderate Bargaining Power of Buyers
3.3.2. Low Bargaining Power of Suppliers
3.3.3. Moderate Threat of Substitutes
3.3.4. Low Threat of New Entrants
3.3.5. Moderate Competitive Rivalry
3.4. Top Player Positioning
3.5. Market Dynamics
3.5.1. Drivers
3.5.1.1. Surge In Severe Road Accidents
3.5.1.2. Significant Increase In Surgical Procedures
3.5.2. Restraint
3.5.2.1. High Cost of These Drugs
3.5.3. Opportunity
3.5.3.1. Various Growth Opportunities In Emerging Economies
Chapter 4: Antifibrinolytic Drugs Market, By Indication
4.1. Overview
4.1.1. Market Size And Forecast
4.2. Gynecology
4.2.1. Key Market Trends And Opportunities
4.2.2. Market Size And Forecast
4.2.3. Market Share Analysis, By Country
4.3. Hereditary Angioedema
4.3.1. Key Market Trends And Growth Opportunities
4.3.2. Market Size And Forecast
4.3.3. Market Share Analysis, By Country
4.4. Fibrinolytic Response Testing
4.4.1. Key Market Trends And Opportunities
4.4.2. Market Size And Forecast
4.4.3. Market Share Analysis, By Country
4.5. Surgeries
4.5.1. Key Market Trends And Opportunities
4.5.2. Market Size And Forecast
4.5.3. Market Share Analysis, By Country
4.6. Others
4.6.1. Key Market Trends And Opportunities
4.6.2. Market Size And Forecast
4.6.3. Market Share Analysis, By Country
Chapter 5: Antifibrinolytic Drugs Market, By End User
5.1. Overview
5.1.1. Market Size And Forecast
5.2. Hospitals
5.2.1. Market Size And Forecast
5.2.2. Market Share Analysis, By Country
5.3. Ambulatory Surgery Centers
5.3.1. Market Size And Forecast
5.3.2. Market Share Analysis, By Country
5.4. Trauma Centers
5.4.1. Market Size And Forecast
5.4.2. Market Share Analysis, By Country
Chapter 6: Antifibrinolytic Drugs Market, By Region
6.1. Overview
6.1.1. Market Size And Forecast
6.2. North America
6.2.1. Key Market Trends And Opportunities
6.2.2. Market Size And Forecast, By Country
6.2.3. Market Size And Forecast, By Indication
6.2.4. Market Size And Forecast, By End User
6.2.5. U.S.
6.2.5.1. U.S. Market Size And Forecast, By Indication
6.2.5.2. U.S. Market Size And Forecast, By End User
6.2.6. Canada
6.2.6.1. Canada Market Size And Forecast, By Indication
6.2.6.2. Canada Market Size And Forecast, By End User
6.2.7. Mexico
6.2.7.1. Mexico Market Size And Forecast, By Indication
6.2.7.2. Mexico Market Size And Forecast, By End User
6.3. Europe
6.3.1. Key Growth Factors And Opportunities
6.3.2. Market Size And Forecast, By Country
6.3.3. Market Size And Forecast, By Indication
6.3.4. Market Size And Forecast, By End User
6.3.5. Germany
6.3.5.1. Germany Market Size And Forecast, By Indication
6.3.5.2. Germany Market Size And Forecast, By End User
6.3.6. France
6.3.6.1. France Market Size And Forecast, By Indication
6.3.6.2. France Market Size And Forecast, By End User
6.3.7. Uk
6.3.7.1. Uk Market Size And Forecast, By Indication
6.3.7.2. Uk Market Size And Forecast, By End User
6.3.8. Italy
6.3.8.1. Italy Market Size And Forecast, By Indication
6.3.8.2. Italy Market Size And Forecast, By End User
6.3.9. Rest of Europe
6.3.9.1. Rest of Europe Market Size And Forecast, By Indication
6.3.9.2. Rest of Europe Market Size And Forecast, By End User
6.4. Asia-Pacific
6.4.1. Key Growth Factors And Opportunities.
6.4.2. Market Size And Forecast, By Country
6.4.3. Market Size And Forecast, By Indication
6.4.4. Market Size And Forecast, By End User
6.4.5. Japan
6.4.5.1. Japan Market Size And Forecast, By Indication
6.4.5.2. Japan Market Size And Forecast, By End User
6.4.6. China
6.4.6.1. China Market Size And Forecast, By Indication
6.4.6.2. China Market Size And Forecast, By End User
6.4.7. India
6.4.7.1. India Market Size And Forecast, By Indication
6.4.7.2. India Market Size And Forecast, By End User
6.4.8. Rest of Asia-Pacific
6.4.8.1. Rest of Asia-Pacific Market Size And Forecast, By Indication
6.4.8.2. Rest of Asia - Pacific Market Size And Forecast, By End User
6.5. Lamea
6.5.1. Key Growth Factors And Opportunities
6.5.2. Market Size And Forecast, By Country
6.5.3. Market Size And Forecast, By Indication
6.5.4. Market Size And Forecast, By End User
6.5.5. Brazil
6.5.5.1. Brazil Market Size And Forecast, By Indication
6.5.5.2. Brazil Market Size And Forecast, By End User
6.5.6. Saudi Arabia
6.5.6.1. Saudi Arabia Market Size And Forecast, By Indication
6.5.6.2. Saudi Arabia Market Size And Forecast, By End User
6.5.7. South Africa
6.5.7.1. South Africa Market Size And Forecast, By Indication
6.5.7.2. South Africa Market Size And Forecast, By End User
6.5.8. Rest of Lamea
6.5.8.1. Rest of Lamea Market Size And Forecast, By Indication
6.5.8.2. Rest of Lamea Market Size And Forecast, By End User
Chapter 7: Company Profiles
7.1. Akorn Inc.
7.1.1. Company Overview
7.1.2. Company Snapshot
7.1.3. Operating Business Segments
7.1.4. Product Portfolio
7.1.5. Business Performance
7.2. Aurobindo Pharma Limited
7.2.1. Company Overview
7.2.2. Company Snapshot
7.2.3. Operating Business Segments
7.2.4. Product Portfolio
7.2.5. Business Performance
7.3. Bayer Ag
7.3.1. Company Overview
7.3.2. Company Snapshot
7.3.3. Operating Business Segments
7.3.4. Product Portfolio
7.3.5. Business Performance
7.4. Ferring Holding Sa
7.4.1. Company Overview
7.4.2. Company Snapshot
7.4.3. Operating Business Segments
7.4.4. Product Portfolio
7.4.5. Business Performance
7.5. Mylan N.V.
7.5.1. Company Overview
7.5.2. Company Snapshot
7.5.3. Operating Business Segments
7.5.4. Product Portfolio
7.5.5. Business Performance
7.6. Novartis International Ag (Sandoz)
7.6.1. Company Overview
7.6.2. Company Snapshot
7.6.3. Operating Business Segments
7.6.4. Product Portfolio
7.6.5. Business Performance
7.7. Pfizer Inc.
7.7.1. Company Overview
7.7.2. Company Snapshot
7.7.3. Operating Business Segments
7.7.4. Product Portfolio
7.7.5. Business Performance
7.8. Sanofi S.A.
7.8.1. Company Overview
7.8.2. Company Snapshot
7.8.3. Operating Business Segments
7.8.4. Product Portfolio
7.8.5. Business Performance
7.9. Takeda Pharmaceutical Company Limited
7.9.1. Company Overview
7.9.2. Company Snapshot
7.9.3. Operating Business Segments
7.9.4. Product Portfolio
7.9.5. Business Performance
7.10. Vitruvias Therapeutics Inc.
7.10.1. Company Overview
7.10.2. Company Snapshot
7.10.3. Operating Business Segments
7.10.4. Product Portfolio
7.10.5. Business Performance
7.10.1. Key Strategic Moves And Developments
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
